Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Jacqueline V. Aredo et al.|Cancer Discovery|2023Cited by 181
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|JAMA Oncology|2024Cited by 35
Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid CancerMaria E. Cabanillas, Naifa L. Busaidy, G. Brandon Gunn et al.|Thyroid|2025Cited by 8
Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a CureMaria E. Cabanillas, Mark Zafereo, Neal S. Akhave et al.|Thyroid|2025Cited by 5
Characterization of Advanced <i>RAS</i> -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic AvenuesSarah Hamidi, Maria E. Cabanillas, Anastasios Maniakas et al.|The Journal of Clinical Endocrinology & Metabolism|2025Cited by 5